Afatinib and Erlotinib in the treatment of squamous-cell lung cancer
M Tagliamento, C Genova, E Rijavec… - Expert Opinion on …, 2018 - Taylor & Francis
… erlotinib and afatinib in SCC of the lung. The authors explore the rationale of targeting EGFR
in SCC and the pharmacological properties of erlotinib … 8 trial, which compared erlotinib and …
in SCC and the pharmacological properties of erlotinib … 8 trial, which compared erlotinib and …
Development and in vitro evaluation of core–shell type lipid–polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer
B Mandal, NK Mittal, P Balabathula, LA Thoma… - European journal of …, 2016 - Elsevier
… erlotinib loaded CSLPHNPs compared to erlotinib solution in A549 cells. Therefore, CSLPHNPs
could be a potential delivery system for erlotinib … erlotinib loaded CSLPHNPs (erlotinib …
could be a potential delivery system for erlotinib … erlotinib loaded CSLPHNPs (erlotinib …
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Y Kuang, A Rogers, BY Yeap, L Wang… - Clinical Cancer …, 2009 - AACR
… In this study we examined the ability to detect EGFR T790M from plasma DNA from
NSCLC patients that had clinically developed acquired resistance to gefitinib or erlotinib. We …
NSCLC patients that had clinically developed acquired resistance to gefitinib or erlotinib. We …
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ
… Aims: This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG)
intended for topical application for the treatment of ductal carcinoma in situ. Materials & …
intended for topical application for the treatment of ductal carcinoma in situ. Materials & …
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells
… the synergistic effect between erlotinib and MAP kinase kinase (MEK) inhibitors in pancreatic
cancer cells and animal models. We show that the combination of erlotinib, an epidermal …
cancer cells and animal models. We show that the combination of erlotinib, an epidermal …
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC
RS Herbst, A Sandler - The Oncologist, 2008 - academic.oup.com
… Although a direct comparison of erlotinib efficacy with that of docetaxel and pemetrexed
will be possible only when data are available from comparative trials, the efficacy of erlotinib …
will be possible only when data are available from comparative trials, the efficacy of erlotinib …
[HTML][HTML] Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor …
S Park, SY Lee, D Kim, YS Sim, JS Ryu, J Choi, SH Lee… - BMC cancer, 2021 - Springer
… We investigated the clinical outcomes of afatinib, erlotinib, and gefitinib according to EGFR
… is uncertain, as comparative studies have been scarce. The present study demonstrated that …
… is uncertain, as comparative studies have been scarce. The present study demonstrated that …
[HTML][HTML] Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy
… cells and shows a synergy with erlotinib. Specifically, the cotreatment of sertraline and …
In this study, we demonstrated that sertraline enhanced the therapeutic efficacy of erlotinib in …
In this study, we demonstrated that sertraline enhanced the therapeutic efficacy of erlotinib in …
[HTML][HTML] EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
… study, we created an EGFR Mutant Structural Database, containing over one hundred EGFR
mutants and their binding free energies with reversible TKIs gefitinib and erlotinib. … erlotinib. …
mutants and their binding free energies with reversible TKIs gefitinib and erlotinib. … erlotinib. …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - The European Journal of …, 2019 - Springer
… After converting the currencies used in the studies to I$, using the CPI and PPP, we found
that erlotinib in the first-line treatment of advanced NSCLC had incremental cost-effectiveness …
that erlotinib in the first-line treatment of advanced NSCLC had incremental cost-effectiveness …